Acrivon Therapeutics, Inc. (ACRV)

NASDAQ: ACRV · IEX Real-Time Price · USD
12.50
-0.35 (-2.72%)
At close: Dec 1, 2022 3:58 PM
12.70
+0.20 (1.60%)
After-hours: Dec 1, 2022 6:25 PM EST

Company Description

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform.

Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candidates.

Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders.

We are currently advancing our lead candidate, ACR-368, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to ACR-368.

Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated in this trial.

We also plan to study ACR-368 in additional indications, such as human papilloma virus positive, squamous cell carcinomas, including squamous cell cancer of head and neck, anal, and cervical cancer.

Acrivon Therapeutics, Inc.
Acrivon Therapeutics logo
Country United States
Founded 2018
IPO Date Nov 15, 2022
Industry Health Care
Sector Pharmaceuticals
Employees 35
CEO Peter Blume-Jensen, M.D., Ph.D.

Contact Details

Address:
480 Arsenal Way, Suite 100
Watertown, MA 02472
United States
Phone (617) 207-8979
Website acrivon.com

Stock Details

Ticker Symbol ACRV
Exchange NASDAQ
Fiscal Year End December
Reporting Currency USD
IPO Price $12.50
CIK Code 0001781174
Employer ID 82-5125532
SIC Code 2834

Key Executives

Name Position
Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Chairman of the Board
Rasmus Holm-Jorgensen Chief Financial Officer
Erick Gamelin, M.D., Ph.D. Chief Medical Officer
Kristina Masson, Ph.D. Executive Vice President, Business Operations, Director
Eric Devroe, Ph.D. Chief Operating Officer
Derek DiRocco, Ph.D. Director
Sharon Shacham, Ph.D., M.B.A. Director
Michael Tomsicek, M.B.A. Director

Latest SEC Filings

Date Type Title
Nov 28, 2022 SC 13D General statement of acquisition of beneficial ownership
Nov 28, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 25, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 21, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 18, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 17, 2022 8-K Current Report
Nov 17, 2022 S-8 Securities to be offered to employees in employee benefit plans
Nov 16, 2022 424B4 Prospectus
Nov 14, 2022 S-1MEF Registration adding securities to prior Form S-1 registration
Nov 14, 2022 FWP Free Writing Prospectus